MAPT and Alzheimer disease: We have reported that the neurosensory retina and hippocampus from 6-month-old Tg2576, a well-established preclinical AD animal model which only expresses the human amyloid precursor protein (APP)695 with Swedish mutation (K670N-M671L), respond in parallel to in vivo selective neutralization of 20–22 kDa toxic N-terminal tau fragments (i.e., NH2htau) following intravenous (i.v.)injection of the cleavage-specific 12A12 conformational monoclonal antibody (mAb) [12,42].